IDH1 and central nervous system cancer: TERTp mutations are relatively rare in diffuse (17.7%, range 10–19%) and anaplastic astrocytomas (24.7%, range 10–62.5%), as well as in IDH-mutated gliomas and secondary GBM (~28%).